Zentalis Pharmaceuticals, Inc.
ZNTLHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeZentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. With a market capitalization of $284.7M, it sits in micro-cap territory. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
Market Cap
$284.7M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-2.57
EPS (TTM)
$-1.74
EPS (Fwd)
$-1.56
ROE
-51.9%
ROA
-27.7%
Cash
$211.8M
Total Debt
$34.6M
Free CF
-$73.3M
52W Change
212.5%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $211.8M in cash comfortably exceeding the $34.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$73.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -51.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing ZNTL's risk profile alongside its fundamentals and technical indicators provides a more complete picture.